Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database

Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database

ObjectivePembrolizumab is a key drug in the immunotherapy of endometrial cancer (EC) and has improved the prognosis to some extent. However, adverse drug events (ADEs) have hindered the achievement of expected therapeutic outcomes in EC. This study, therefore, aims to investigate the ADEs of pembrol...

Full description

Saved in:
Bibliographic Details
Main Authors: Huiping Zhang, Man Di, Jingjing Wang, Shan Wang, Yini Dai, Jingjing Huang, Zhuo Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Pharmacology
Subjects:
pembrolizumab
endometrial cancer
immunotherapy
immune checkpoint inhibitors
immune-related adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1622339/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items